SCHEMBL1838720

SCHEMBL1838720

CC(C)N(C(=O)ONC(=N)c1ccc2[nH]c(-c3ccc(F)cc3)nc2c1)C(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 7/20 0.47
NR4A2 P43354 1/20 0.46
RHEB Q15382 1/20 0.41
KDM4E B2RXH2 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
PKM P14618 1/20 0.41
HPGD P15428 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
HDAC3 O15379 2/20 0.40
HDAC1 Q13547 2/20 0.40
HDAC2 Q92769 2/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
MMP2 P08253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1840141 0.87 CHEK2 (0.51) CHEK2NR4A2RHEBKDM4ENPC1
SCHEMBL1840659 0.86 CHEK2 (0.47) CHEK2NR4A2RHEBKDM4ENPC1
SCHEMBL1838700 0.86 CHEK2 (0.48) CHEK2NR4A2RHEBKDM4ENPC1
SCHEMBL1841822 0.85 CHEK2 (0.47) CHEK2NR4A2RHEBKDM4ENPC1
SCHEMBL10029166 0.84 CHEK2 (0.51) CHEK2NR4A2RHEBKDM4ENPC1
SCHEMBL1840992 0.81 CHEK2 (0.47) CHEK2NR4A2RHEBKDM4ENPC1
SCHEMBL1840298 0.81 CHEK2 (0.47) CHEK2NR4A2RHEBKDM4ENPC1
SCHEMBL1841109 0.77 NR4A2 (0.52) CHEK2NR4A2KDM4ENPC1RAB9A
SCHEMBL3922046 0.74 CHEK2 (0.81) CHEK2NR4A2
SCHEMBL10029169 0.73 CHEK2 (0.53) CHEK2NR4A2RHEBKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8168665-B2 Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2012-05-01 US claimed
EP-2079709-B1 SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI AVENTIS (FR) 2011-05-18 EP claimed
US-20090239915-A1 Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2009-09-24 US claimed
EP-2079709-A1 SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2009-07-22 EP claimed
WO-2008037381-A1 SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-04-03 WO claimed
EP-1905764-A1 Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals Sanofi-Aventis (FR) 2008-04-02 EP claimed
US-8168665-B2 Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2012-05-01 US disclosed
EP-2079709-B1 SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI AVENTIS (FR) 2011-05-18 EP disclosed
US-20090239915-A1 Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2009-09-24 US disclosed
EP-1905764-A1 Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals Sanofi-Aventis (FR) 2008-04-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239915-A1 Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals NOS2, NOS3, NOS1 CHEK2 4134/4885NR4A2 983/4885RHEB 2697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.